Sugi Predict

Sugi Predict / Targets / PTK2

PTK2

Focal adhesion kinase 1 · Q05397 · PTK2 on Sugi Atlas →

161,525 patent compounds predicted against PTK2, 105,073 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL30925 SCHEMBL30925 0.64 20/20
SCHEMBL20626 SCHEMBL20626 0.59 19/20
SCHEMBL21039 SCHEMBL21039 0.53 19/20
SCHEMBL19153 SCHEMBL19153 0.58 17/20
SCHEMBL20543 SCHEMBL20543 0.57 17/20
SCHEMBL19111 SCHEMBL19111 0.56 17/20
SCHEMBL24181 SCHEMBL24181 0.56 16/20
SCHEMBL20007 SCHEMBL20007 0.53 16/20
SCHEMBL30932 SCHEMBL30932 0.46 14/20
SCHEMBL20311 SCHEMBL20311 0.44 13/20
SCHEMBL30966 SCHEMBL30966 0.57 12/20
SCHEMBL20394 SCHEMBL20394 0.57 12/20
SCHEMBL19675 SCHEMBL19675 0.53 12/20
SCHEMBL20913 SCHEMBL20913 0.51 12/20
SCHEMBL19518 SCHEMBL19518 0.56 11/20
SCHEMBL24046 SCHEMBL24046 0.55 11/20
SCHEMBL24033 SCHEMBL24033 0.44 11/20
SCHEMBL25496 SCHEMBL25496 0.54 10/20
SCHEMBL24481 SCHEMBL24481 0.54 10/20
SCHEMBL24145 SCHEMBL24145 0.51 10/20

Clinical trials — most relevant to PTK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
Protein Tyrosine Kinases (PTK) in Multiple Myeloma PHASE2COMPLETED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions PHASE1/PHASE2COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP) PHASE1/PHASE2COMPLETED
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia PHASE2COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer PHASE2COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer PHASE1/PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS PHASE1RECRUITING
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma EARLY_PHASE1ACTIVE_NOT_RECRUITING
Histological and Molecular Mechanisms of Pain in Patient With Chronic Pain From Adhesions nanCOMPLETED
Indoxyl Sulfate Induces Leukocyte-endothelial Interactions Through Up-regulation of ICAM-1 in Acute Kidney Injury nanUNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases nanNOT_YET_RECRUITING
Evaluation of a New Approach of the Diagnosis of Constitutional Functional Disorders of Platelets nanCOMPLETED
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations nanWITHDRAWN
Prospective Monocentric Clinical-biological Database nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PTK2 binder may also engage these)

ProteinNameSimilarity
O35346 — 1.000 O35346 →
P34152 — 1.000 P34152 →
Q00944 — 1.000 Q00944 →
Q91738 — 1.000 Q91738 →
PTK2B Protein-tyrosine kinase 2-beta 0.996 landscape →
Q61084 — 0.993 Q61084 →
MAP3K3 Mitogen-activated protein kinase kinase kinase 3 0.993 landscape →
P70600 — 0.992 P70600 →
Q61083 — 0.992 Q61083 →
A2VDU3 — 0.992 A2VDU3 →
Q62073 — 0.992 Q62073 →
Q9QVP9 — 0.990 Q9QVP9 →
O43295 — 0.990 O43295 →
P0C8E4 — 0.989 P0C8E4 →
Q9VZI3 — 0.989 Q9VZI3 →
Q8C0D4 — 0.989 Q8C0D4 →
E9PUQ8 — 0.989 E9PUQ8 →
Q5M824 — 0.989 Q5M824 →
Q9Y4G8 — 0.988 Q9Y4G8 →
Q2I6J1 — 0.988 Q2I6J1 →
Q812E4 — 0.988 Q812E4 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.988 landscape →
Q5R5M7 — 0.987 Q5R5M7 →
O15068 — 0.987 O15068 →
P11346 — 0.987 P11346 →
P11345 — 0.987 P11345 →
F1M386 — 0.987 F1M386 →
P87253 — 0.987 P87253 →
Q92503 — 0.987 Q92503 →
F1PBJ0 — 0.987 F1PBJ0 →